Pacira BioSciences, Inc. announced two key appointments to its executive leadership team. Brendan Teehan has been named Chief Commercial Officer and Krys Corbett, Esq. has been named Chief Business Officer.
Mr. Teehan is an accomplished biopharmaceutical executive with a 30-year track record of successfully building and leading commercial teams. He brings extensive expertise in both privately and publicly held companies across multiple large and rare disease therapeutic categories and development stages. Prior to joining Pacira, Mr. Teehan held various commercial leadership positions at Acadia Pharmaceuticals, Inc., most recently as Chief Operating Officer and Head of Commercial where he was responsible for all commercial functions. Prior to Acadia, he served in a variety of commercial leadership roles at Tesaro, Inc., Raintree Oncology Services, Amgen, Inc., and Johnson & Johnson.
Mr. Teehan holds a B.A. in Government and Political Science from the University of Notre Dame and an M.B.A. from Carnegie Mellon University. Ms. Corbett brings more than 25 years of industry experience across business development, strategic transactions, alliance management, and product portfolio management to Pacira. Prior to joining Pacira, she led portfolio and product strategy for clinical and preclinical-stage programs at Lyell Immunopharma.
Before that, Ms. Corbett was Head of Business Development, General Counsel, and Corporate Secretary for Oric Pharmaceuticals. Earlier in her career, she served in alliance and asset management leadership roles at Roche and Genentech. Ms. Corbett began her career at the law firm Wilson Sonsini Goodrich and Rosati.
She holds a B.A. in Political Science from Brigham Young University and a J.D. from Duke University.